AbbVie HCV regimen gets breakthrough designation

AbbVie Inc. (NYSE:ABBV) said FDA granted breakthrough therapy designation to its glecaprevir/pibrentasvir regimen to treat chronic HCV genotype 1 infection in patients who have failed therapy with direct-acting antivirals (DAAs). AbbVie is developing the regimen as a pan-genotypic HCV therapy.

Glecaprevir ( ABT-493) is a next-generation HCV NS3/4A protease inhibitor. Pibrentasvir ( ABT-530) is a next-generation HCV NS5A protein inhibitor. ...